​

Neuphoria Therapeutics Stock (NASDAQ:NEUP)

OwnershipFinancialsChart
Neuphoria Therapeutics by TradingView

Previous Close

$4.42

52W Range

$3.65 - $21.40

50D Avg

$4.93

200D Avg

$6.27

Market Cap

$24.27M

Avg Vol (3M)

$51.71K

Beta

0.72

Div Yield

-

NEUP Company Profile

Neuphoria Therapeutics, Inc. is a biotechnology company currently advancing treatments through clinical trials. Its core mission involves pioneering therapies specifically engineered to address the intricate requirements of individuals living with neuropsychiatric disorders. The company was established on December 23, 2024, and its main corporate offices are located in Burlington, Massachusetts.

Show More

Industry

Medical - Pharmaceuticals

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

8

IPO Date

Dec 16, 2021

Website

NEUP Performance

NEUP Financial Summary

Jun 24Jun 23Jun 22
Revenue-$20.00K$260.00K
Operating Income$-17.89B$-31.97M$-21.34M
Net Income$-15.49B$-31.85M$-21.76M
EBITDA$-17.89B$-17.87M$-11.51M
Basic EPS$-0.01$-0.02$-0.02
Diluted EPS$-0.01$-0.02$-0.02

Fiscal year ends in Jun 24 | Currency in USD

Peer Comparison

TickerCompany
ALZNAlzamend Neuro, Inc.
PTHLPheton Holdings Ltd Class A Ordinary Shares
PFSAProfusa, Inc. Common Stock
LFWDLifeward Ltd.
LUCYInnovative Eyewear, Inc.
BMRABiomerica, Inc.
APREAprea Therapeutics, Inc.
BCDABioCardia, Inc.
IINNInspira Technologies Oxy B.H.N. Ltd.